Future directions of Liquid Biopsy in monitoring of melanoma patients
|
|
- Buck Armstrong
- 5 years ago
- Views:
Transcription
1 Future directions of Liquid Biopsy in monitoring of melanoma patients Verena Haselmann, MD PhD Institute for Clinical Chemistry University of Mannheim, Germany
2 Circulating tumor DNA (ctdna)
3 ctdna - advantages High compliance Minimal invasive, few risks High availability Archival tissue, degraded, different mutation profile Patient/Oncologist Physician Specialist e.g. Surgeon Accessible No selection bias Assess primary tumor and metastases with one sample, tumor heterogeneity not a problem Monitoring possible Pathology Clinical Laboratory Real-time
4 Future development: MRD 1st line: Tumor Tissue (FFPE) Targeted resequencing (NGS) only performed once Identification of an individual tumor mutational profile 2nd line: Plasma Follow up for MRD-Diagnostic - performed on a regular basis Analyis of biomarkers and liquid profiling of individual tumor mutations Reduce lead time compared to imaging?
5 Future development: Companion Diagnostics 1st line: Plasma Targeted reanalysis of ctdna Identification of pharmacogentic relevant tumor mutations in real-time Follow up of the identified mutations for monitoring of treatment response Gene Mutation BRAF BRAF V600E (T1799A) BRAF V600K (GT1798_1799AA) EGFR EGFR L858R (T2573G) EGFR Del 19 (including E746_S752>V ( D) EGFR L747_A750>P ( D) EGFR L747_T751del ( D) EGFR L747_P753>S ( D) EGFR E746_A750del* ( D, D) KRAS G12S (G34A) KRAS KRAS G12R (G34C) KRAS G12C (G34T) KRAS G12D (G35A) KRAS G12A (G35C) KRAS G12V (G35T) KRAS G13D (G38A) KRAS G61H (A183C/T) NRAS NRAS Q61K (C181A) NRAS Q61R (A182G) NRAS Q61L (A182T) NRAS Q61H (A183T) PIK3CA PIK3CA E542K (G1624A) PIK3CA E545K (G1633A) PIK3CA E545G (A1634G) PIK3CA Q546K (C1636A) PIK3CA M1043I (G3129T) PIK3CA H1047Y (C3139T) PIK3CA H1047R (A3140G) PIK3CA H1047L (A3140T)
6 ctdna technical challenges Netherlands; 2 Denmark; 1 Italy; 3 Switzerland; 1 Austria; 4 Belgium; 5 Highly fragmented Mean size bp Czech Republic; 2 Germany France; 4 Germany; 12 Greece; 3 Greece France Belgium Italy Denmark Netherlands Austria Switzerland Czech Republic ctdna fraction very low E.g. less than 0.02 % Risk of contamination E.g. with wildtype DNA from leukocytes National Cancer Institute Schwarzenbach et al 2011, Nat Rev Cancer Thiery et al 2013, Nat Medicine
7 ctdna detection methods Detection Capability (mutant DNA/ total DNA) 100% 10% Sanger Sequencing Pyrosequencing 1% Real-time PCR Next Generation Sequencing 0.1% COLD-PCR, ASA, ARMS, % BEAMing, ddpcr, TAmSeq, SafeSeq,... Li et al. 2006, Nat Methods Li et al. 2008, Nat Medicine Forshew et al Sci Trans Med
8 ctdna detection methods Detection Capability (mutant DNA/ total DNA) 100% 10% Sanger Sequencing Pyrosequencing 1% Real-time PCR Next Generation Sequencing 0.1% COLD-PCR, ASA, ARMS, % BEAMing, ddpcr, TAmSeq, SafeSeq,... Li et al. 2006, Nat Methods Li et al. 2008, Nat Medicine Forshew et al Sci Trans Med
9 Study design pharmacogenetic target Hodis et al., Cell. 2012
10 Study design pharmacogenetic target Hodis et al., Cell. 2012
11 Study design detection method sysmex.co.jp
12 Study design validation of detection method
13 Study design currently available study data Yankovitz et al., 2007, Journal of Molecular Diagnostics: 26 stage IV melanoma patients, concordance 59%, ASA, blood-samples stored on ice before plasmaseparation, thawed plasma was centrifuged and the pellet (gdna from leukocytes) was used for analysis Aung et al., 2009, Journal of Molecular Diagnostics: 221 stage IV melanoma patients, specificity 94%, sensitivity 42%, ARMS, no information regarding blood-draw, partly used serum Board, 2009, British Journal of Cancer: 96 stage IV melanoma patients, concordance 56%, serum, ARMS Pinzani et al., 2010, Clinica Chimica Acta: 55 melanoma patients, different stages, concordance 80%, selfdeveloped real-time-based approach, assay sensitivity 0.03% Fusi et al, 2011, European Journal of Cancer: 21 stage IV melanoma patients, concordance 91%, selfdeveloped assay, no information regarding pre-analytical sample handling Ascierto et al, 2013, Clinical Oncology: 76 stage IV melanoma patients, sensitivity 79%, specificity 100%, BEAMing, no information regarding pre-analytical sample handling, assay conducted by company Lipson et al., 2014, Journal for ImmunoTherapy of Cancer: 12 stage IV melanoma patients, BEAMing, ctdna versus imaging Tsao et al., 2015, Scientific Reports: 6 stage IV melanoma patients, ddpcr, ctdna versus LDH Sanmamed et al., 2015, Clinical Chemistry: 20 melanoma patients under BRAFi, concordance 84%, ddpcr, only one centrifugation step, too high g-forces A. Santiago-Walker et al., 2015, Clinical Cancer Research: 732 melanoma patients, different stages, e.g. stage IV, concordance 76%, BEAMing, no information regarding pre-analytics, assay conducted by company Gonzalez-Cao et al., 2015, Melanoma Research: 92 stage III and IV melanoma patients, sensitivity 57%, specificity 100%, serum and plasma, self-developed assay, no information regarding storage duration until plasma separation Gray et al, 2015, Oncotarget: 48 stage IV melanoma patients, concordance 65%, ddpcr, plasma separation within 24h, different plasma volumes Schreuer et al, 2016, Journal of Translational Medicine: 35 stage IV melanoma patients, sensitivity 75%, no wild-type patients included, ASA, 1ml plasma used, 1 centrifugation step
14 Study design currently available study data Yankovitz et al., 2007, Journal of Molecular Diagnostics: 26 stage IV melanoma patients, concordance 59%, ASA, blood-samples stored on ice before plasmaseparation, thawed plasma was centrifuged and the pellet (gdna from leukocytes) was used for analysis Aung et al., 2009, Journal of Molecular Diagnostics: 221 stage IV melanoma patients, specificity 94%, sensitivity 42%, ARMS, no information regarding blood-draw, partly used serum Board, 2009, British Journal of Cancer: 96 stage IV melanoma patients, concordance 56%, serum, ARMS Pinzani et al., 2010, Clinica Chimica Acta: 55 melanoma patients, different stages, concordance 80%, selfdeveloped real-time-based approach, assay sensitivity 0.03% Fusi et al, 2011, European Journal of Cancer: 21 stage IV melanoma patients, concordance 91%, selfdeveloped assay, no information regarding pre-analytical sample handling Ascierto et al, 2013, Clinical Oncology: 76 stage IV melanoma patients, sensitivity 79%, specificity 100%, BEAMing, no information regarding pre-analytical sample handling, assay conducted by company Lipson et al., 2014, Journal for ImmunoTherapy of Cancer: 12 stage IV melanoma patients, BEAMing, ctdna versus imaging Tsao et al., 2015, Scientific Reports: 6 stage IV melanoma patients, ddpcr, ctdna versus LDH Sanmamed et al., 2015, Clinical Chemistry: 20 melanoma patients under BRAFi, concordance 84%, ddpcr, only one centrifugation step, too high g-forces A. Santiago-Walker et al., 2015, Clinical Cancer Research: 732 melanoma patients, different stages, e.g. stage IV, concordance 76%, BEAMing, no information regarding pre-analytics, assay conducted by company Gonzalez-Cao et al., 2015, Melanoma Research: 92 stage III and IV melanoma patients, sensitivity 57%, specificity 100%, serum and plasma, self-developed assay, no information regarding storage duration until plasma separation Gray et al, 2015, Oncotarget: 48 stage IV melanoma patients, concordance 65%, ddpcr, plasma separation within 24h, different plasma volumes Schreuer et al, 2016, Journal of Translational Medicine: 35 stage IV melanoma patients, sensitivity 75%, no wild-type patients included, ASA, 1ml plasma used, 1 centrifugation step
15 Study design currently available study data Yankovitz et al., 2007, Journal of Molecular Diagnostics: 26 stage IV melanoma patients, concordance 59%, ASA, blood-samples stored on ice before plasmaseparation, thawed plasma was centrifuged and the pellet (gdna from leukocytes) was used for analysis Aung et al., 2009, Journal of Molecular Diagnostics: 221 stage IV melanoma patients, specificity 94%, sensitivity 42%, ARMS, no information regarding blood-draw, partly used serum Board, 2009, British Journal of Cancer: 96 stage IV melanoma patients, concordance 56%, serum, ARMS Pinzani et al., 2010, Clinica Chimica Acta: 55 melanoma patients, different stages, concordance 80%, selfdeveloped real-time-based approach, assay sensitivity 0.03% Fusi et al, 2011, European Journal of Cancer: 21 stage IV melanoma patients, concordance 91%, selfdeveloped assay, no information regarding pre-analytical sample handling Ascierto et al, 2013, Clinical Oncology: 76 stage IV melanoma patients, sensitivity 79%, specificity 100%, BEAMing, no information regarding pre-analytical sample handling, assay conducted by company Lipson et al., 2014, Journal for ImmunoTherapy of Cancer: 12 stage IV melanoma patients, BEAMing, ctdna versus imaging Tsao et al., 2015, Scientific Reports: 6 stage IV melanoma patients, ddpcr, ctdna versus LDH Sanmamed et al., 2015, Clinical Chemistry: 20 melanoma patients under BRAFi, concordance 84%, ddpcr, only one centrifugation step, too high g-forces A. Santiago-Walker et al., 2015, Clinical Cancer Research: 732 melanoma patients, different stages, e.g. stage IV, concordance 76%, BEAMing, no information regarding pre-analytics, assay conducted by company Gonzalez-Cao et al., 2015, Melanoma Research: 92 stage III and IV melanoma patients, sensitivity 57%, specificity 100%, serum and plasma, self-developed assay, no information regarding storage duration until plasma separation Gray et al, 2015, Oncotarget: 48 stage IV melanoma patients, concordance 65%, ddpcr, plasma separation within 24h, different plasma volumes Schreuer et al, 2016, Journal of Translational Medicine: 35 stage IV melanoma patients, sensitivity 75%, no wild-type patients included, ASA, 1ml plasma used, 1 centrifugation step
16 Study design currently available study data Yankovitz et al., 2007, Journal of Molecular Diagnostics: 26 stage IV melanoma patients, concordance 59%, ASA, blood-samples stored on ice before plasmaseparation, thawed plasma was centrifuged and the pellet (gdna from leukocytes) was used for analysis Aung et al., 2009, Journal of Molecular Diagnostics: 221 stage IV melanoma patients, specificity 94%, sensitivity 42%, ARMS, no information regarding blood-draw, partly used serum Board, 2009, British Journal of Cancer: 96 stage IV melanoma patients, concordance 56%, serum, ARMS Pinzani et al., 2010, Clinica Chimica Acta: 55 melanoma patients, different stages, concordance 80%, selfdeveloped real-time-based approach, assay sensitivity 0.03% Fusi et al, 2011, European Journal of Cancer: 21 stage IV melanoma patients, concordance 91%, selfdeveloped assay, no information regarding pre-analytical sample handling Ascierto et al, 2013, Clinical Oncology: 76 stage IV melanoma patients, sensitivity 79%, specificity 100%, BEAMing, no information regarding pre-analytical sample handling, assay conducted by company Lipson et al., 2014, Journal for ImmunoTherapy of Cancer: 12 stage IV melanoma patients, BEAMing, ctdna versus imaging Tsao et al., 2015, Scientific Reports: 6 stage IV melanoma patients, ddpcr, ctdna versus LDH Sanmamed et al., 2015, Clinical Chemistry: 20 melanoma patients under BRAFi, concordance 84%, ddpcr, only one centrifugation step, too high g-forces A. Santiago-Walker et al., 2015, Clinical Cancer Research: 732 melanoma patients, different stages, e.g. stage IV, concordance 76%, BEAMing, no information regarding pre-analytics, assay conducted by company Gonzalez-Cao et al., 2015, Melanoma Research: 92 stage III and IV melanoma patients, sensitivity 57%, specificity 100%, serum and plasma, self-developed assay, no information regarding storage duration until plasma separation Gray et al, 2015, Oncotarget: 48 stage IV melanoma patients, concordance 65%, ddpcr, plasma separation within 24h, different plasma volumes Schreuer et al, 2016, Journal of Translational Medicine: 35 stage IV melanoma patients, sensitivity 75%, no wild-type patients included, ASA, 1ml plasma used, 1 centrifugation step
17 Study design pre-analytics K3 EDTA-blood Plasma separation within 6h (2. centrifugation steps, 1st at 1600g, 2nd at 3000g) Storage plasma at -80 C 2ml EDTA-plasma for each analysis Isolation cfdna with Qiagen Circulating Nucleic Acid Kit Storage isolated cfdna at -20 C Quantification isolated ctdna with LINE1 real-time PCR Mutational analysis with BEAMing (including negative, positive and non-template control)
18 Study design cohorts Study 1: 1216 prospectively collected EDTA blood-samples from 441 melanoma patients Cohort Mannheim: stage III and IV melanoma patients, mutational data from archival tumor specimens being available Cross-section cohort: all stages BRAFi cohort: patients undergoing active or imminent therapy with BRAFi and MEKi Study 2: comprised 71 retrospectively analyzed EDTA blood samples from metastatic melanoma patients
19 1. Concordance study Cohort Mannheim Cohort Essen Number of Patients n=136 (%) n=71 (%) sex m 80 (58.8) 46 (64.8) f 56 (41.2) 25 (35.2) Age Median 65 63,3 range Stage IV 72 (52.9) 71 (100) IIIc 13 (9.6) 0 (0) IIIb 29 (21.3) 0 (0) IIIa 22 (16.2) 0 (0) Tissue-based analysis BRAF V600E mutation 62 (45.6) 27 (38.0) other BRAF mutation 4 (2.9) 9 (12.7) NRAS mutation 11 (8.1) 12 (16.9) ckit mutation 4 (2.9) n.a. no mutation 55 (40.4) 23 (32.4) Plasma-based number of samples analysis analysed mean number of tests per patient BRAF V600E mutation 40 (29.4) 25 (35.2) no mutation 96 (70.6) 46 (64.8)
20 1. Concordance study Cohort Mannheim Cohort Essen Number of Patients n=136 (%) n=71 (%) Plasma-based analysis Positive for BRAFV600E 34 (25.0) 24 (33.8) Negative for BRAFV600E 92 (67.6) 42 (59.2) False-negative* 5 (3.7) 4 (5.6) False positive# 5 (3.7) 1 (1.4) Statistical analysis Positive agreement 34/39 (87.2) 24/28 (85.7) Negative agreement 92/97 (94.8) 42/43 (97.7) Overall agreement 126/136 (92.6) 66/71 (92.3) kappa 0,82 0,85 SE of kappa 0,055 0,064 95% CI from to from to Number of observed agreements 126 (92.65%) 66 (92.96%) Number of aggreemnets expected by chance 80.4 (59.09%) 37.7 (53.12%) *wildtype instead of BRAFV600E mutant #BRAFV600E mutant instead of wildtype results considered concordant according to clinical situation at the time of the blood draw for Cohort Mannheim
21 1. Concordance study Patients of interest Number of patients n=24 (%) Beaming negative with known tissue BRAF mutation* post resection of melanoma at time of blood draw 14 (58.3) CR/PR under treatment at time of blood draw 6 (25.0) Beaming positive with known tissue BRAF wildtype status at time of blood draw* Secondary BRAF mutant neoplasia 2 (8.3) Secondary BRAF mutant melanoma False negative histologic examination 1 (4.2) 1 (4.2) *results adjusted according to clinical situation at time of blood draw
22 2. Cross-section study Cohorte crosssection analysis Number of Patients n=440 (%) sex m 239 (54.3) f 201 (45.7) Age Median 66 range Stage IV 65 (14.8) IIIc 22 (5.0) IIIb 51 (11.6) IIIa 44 (10.0) Iic 8 (1.8) Iib 33 (7.5) Iia 44 (10.0) Ib 99 (22.5) Ia 68 (15.5) other skin tumor 6 (1.4) Tissue-based analysis BRAF V600E mutation 83 (18.9) other BRAF mutation 4 (0.9) NRAS mutation 11 (2.5) ckit mutation 4 (0.9) no mutation 80 (18.2) n.a. 258 (58.6) Plasma-based analysis number of samples analysed 1211 mean number of tests per patient 2,8 BRAF V600E mutation 57 (13.0) no mutation 383 (87.0) Melanoma subtype cutaneous n.a. mucosal n.a. occult n.a. other n.a. n.a. n.a.
23 2. Cross-section study Cohort cross-section analysis Number of Patients n=440 (%) Plasma-based analysis Positive for BRAFV600E 39 (8.9) Negative for BRAFV600E 377 (85.7) False-negative* 6 (1.4) False positive# 18 (4.1) Statistical analysis Positive agreement 39/45 (86.7) Negative agreement 377/395 (95.4) Overall agreement 416/440 (94.5) kappa 0,734 SE of kappa 0,051 *wildtype instead of BRAFV600E mutant #BRAFV600E mutant instead of wildtype 95% CI from to Number of observed agreements 416 (94.55%) Number of aggreemnets expected by chance (79.47%) *results adjusted according to clinical situation at time of blood draw
24 2. Cross-section study Patients of interest Number of patients n=34 (%) Beaming negative with known BRAF mutation* post resection of melanoma at time of blood draw CR/PR under treatment at time of blood draw 20 (58.8) 6 (17.6) Beaming positive with known BRAF wildtype status at time of blood draw* Secondary BRAF mutant neoplasia 2 (5.9) Secondary BRAF mutant melanoma 5 (14.7) False negative histologic examination 1 (2.9)
25 3. BRAFi study BRAF before treatment 15 weeks of treatment Chapman et al 2011, NEJM Hirth et al. 2012, Nat Drug Discov Wagle et al., JCO 2011
26 3. BRAFi study BRAF before treatment 15 weeks of treatment relapse 23 weeks of therapy Chapman et al 2011, NEJM Hirth et al. 2012, Nat Drug Discov Wagle et al., JCO 2011
27 3. BRAFi study BRAFi cohort Number of Patients n=35 (%) sex Men 18 (51 4) Women 17 (48 6) Age Median 59 4 range Stage IIIC (unresectable) 4 (11 4) Stage IV 31 (88 6) M1a 1 (2 9) M1b 4 (11 4) M1c 26 (74 3) LDH 20 (57 1) Brain metastases 18 (51 4) BRAF status V600E 35 (100) BEAMing positive 35 (100) Plasma-based analysis number of samples analysed 134 mean number of tests per patient 3 83 Mean cfdna level (GE/ml) 95,540 Mean ctdna level (GE/ml) 2,789 Mean ctdna fraction (%) 1 27 BRAFi/MEKi treatment V+C 7 (20 0) D+T 10 (28 6) V mono 15 (42 9) D mono 3 (8 6) Median Duration of Treatment (months) 17 7 Median Time to Resistance (months) 9 1 Median Overall Survival (95% CI) (months) 23 0 ( ) Line of Treatment First-line 32 (91 4) Second-line 2 (5 7) Third-line 1 (2 9) Best overall response Complete response 4 (11 4) Partial response 11 (31 4) Stable disease 9 (25 8) Progressive disease 11 (31 4)
28 Tumor S-100 volume µg/l mm LDH S-100 U/l µg/l LDH U/l Tumor volume mm Study 3: BRAFi Mutant fragments per ml plasma Case 1: Patient #52 Patient # BRAFi therapy Time since BRAFi in days Mutant fragments per ml plasma Patient # BRAFi therapy Mutant fragments 400 per ml plasma Tumor volume mm 300 (complete) 200 Tumor volume mm (brain) Time since BRAFi in days Mutant Mutant fragments fragments per ml per plasma ml plasma Mutant fragments per ml plasma Mutant fragments per ml plasma Patient #52 Patient # BRAFi therapy Mutant fragments Patient # per ml plasma Patient # LDH Time since BRAFi in days Time since BRAFi in days Time since BRAFi in days Mutant fragments per Mutant ml plasma fragments per ml plasma Tumor volume mm (complete) S-100 Tumor Mutant volume fragments mm (brain) Mutant per ml plasma fragments per LDHml plasma S-100
29 3. BRAFi study Plasma-based testing versus imaging techniques: Mean lead time reduction: 110 days (in cases a PD was detected earlier: 170 days)
30 Acknowledgement Institut für Klinische Chemie, UMM Prof. Dr. Michael Neumaier Ingrid Brechtel Angelika Duda Maximillian Kittel Sysmex, Hamburg Prof. Dr. Harmut Juhl Dr. Frank Diehl Dr. Barbara Behrens Dr. Frederick S. Jones Klinik für Dermatologie, UMM DFKZ, Heidelberg Prof. Dr. Jochen Utikal Dr. Christoffer Gebhardt Dr. Tim Holland-Letz Klinik für Dermatologie, UK-Essen Prof. Dr. Dirk Schadendorf Dr. Antje Sucker
Disclosure. Summary. Circulating DNA and NGS technology 3/27/2017. Disclosure of Relevant Financial Relationships. JS Reis-Filho, MD, PhD, FRCPath
Circulating DNA and NGS technology JS Reis-Filho, MD, PhD, FRCPath Director of Experimental Pathology, Department of Pathology Affiliate Member, Human Oncology and Pathogenesis Program Disclosure of Relevant
More informationIntroduction to liquid biopsies. Rachel Butler All Wales Genetics Laboratory
Introduction to liquid biopsies Rachel Butler All Wales Genetics Laboratory What is cell free DNA? Non-Invasive Prenatal Testing (NIPT) Extract DNA Genetic alterations detectable in circulating cell-free
More informationPersonalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes The need for improved diagnostics At the advanced edge of oncology, rapid access to accurate data on disease state is vital. Current technologies such as
More informationTissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~
16 th Dec. 2016. ESMO Preceptorship Program Non-Small-Cell Lung Cancer @Singapore Tissue or Liquid Biopsy? ~For Diagnosis, Monitoring and Early detection of Resistance~ Research Institute for Disease of
More informationPRECISION INSIGHTS. Liquid GPS. Blood-based tumor profiling and quantitative monitoring. Reveal more with cfdna + cfrna.
PRECISION INSIGHTS Liquid GPS Blood-based tumor profiling and quantitative monitoring Reveal more with cfdna + cfrna www.nanthealth.com Why Blood-Based Tumor Profiling? Although tissue-based molecular
More informationMUTATION TEST CE IVD. ctnras-braf FEATURES
ctnras-braf CE IVD TECHNICAL SHEET IDYLLA ctnras-braf MUTATION TEST The Idylla ctnras-braf Mutation Test, performed on the Biocartis Idylla System, is an in vitro diagnostic test for the qualitative detection
More informationUrinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring. Summit August 19,2015
Urinary ctdna Platform for Diagnosis and Cancer Treatment Monitoring Mark G. Erlander, Ph.D., CSO CHI Next Generation Summit August 19,2015 Circulating Tumor DNA (ctdna) Tumor cells Main Advantages of
More informationLa biopsia liquida. Aldo Scarpa. Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro
La biopsia liquida Aldo Scarpa Anatomia Patologica e ARC-NET Centro di Ricerca Applicata sul Cancro Azienda Ospedaliera Universitaria Integrata di Verona Obstacles to precision oncology Genomic heterogeneity
More informationQIAGEN Complete Solutions for Liquid Biopsy Molecular Testing
QIAGEN Complete Solutions for Liquid Biopsy Molecular Testing Christopher Swagell, PhD Market Development Manager, Advanced Molecular Pathology QIAGEN 1 Agenda QIAGEN Solid Tumor Testing and Liquid Biopsy
More informationEGFR ctdna Testing. Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester
EGFR ctdna Testing Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester ctdna & EGFR Testing in NSCLC EGFR ctdna testing Non-invasive - patients too sick/biopsy or cytology
More informationClinical molecular profiling to detect targetable alterations in archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease
ECD International Medical Symposium Paris, France September 15, 2016 Clinical molecular profiling to detect targetable alterations in archival tumor tissue and cell-free DNA from patients with Erdheim-Chester
More informationLiquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
More informationLiquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
More informationNGS in tissue and liquid biopsy
NGS in tissue and liquid biopsy Ana Vivancos, PhD Referencias So, why NGS in the clinics? 2000 Sanger Sequencing (1977-) 2016 NGS (2006-) ABIPrism (Applied Biosystems) Up to 2304 per day (96 sequences
More informationCLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases
CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases Adriana Muniz 1, Mariko Matsutani 1, Karena Kosco 1, John Spinosa 1, Cecile
More informationThe OncoBEAM Platform: The Use of a High Sensitive Technology for Liquid Biopsies in Clinical Practice
The OncoBEAM Platform: The Use of a High Sensitive Technology for Liquid Biopsies in Clinical Practice Sysmex Inostics Dr. Friederike Lehmann Head of CRO Marketing Sysmex Corporation Kobe 2 Sysmex Corporation
More informationUtility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017
Utility of liquid biopsies EQA Program Naples, IT Sidney A. Scudder, MD Director, Clinical Science 13 May, 2017 picture placeholder Agenda cobas EGFR Mutation Test v2 Ring Trial SQI Semi Quantitative Index
More informationLiquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System
Liquid Biopsy Applications on the Idylla Fully Integrated Sample-to-Result MDx System Erwin Sablon, Head of R&D, Biocartis NV World CDx, Boston, September 10 th 2015 0 About Biocartis Innovative molecular
More informationCell-free tumor DNA for cancer monitoring
Learning objectives Cell-free tumor DNA for cancer monitoring Christina Lockwood, PhD, DABCC, DABMGG Department of Laboratory Medicine 1. Define circulating, cell-free tumor DNA (ctdna) 2. Understand the
More informationConflict of Interest Disclosure
"NRAS mutation status in advanced melanoma: how much does this really matter to prognosis and therapy?" John Jakob, MD, PhD Department of Melanoma Medical Oncology, The University of Texas M.D. Anderson
More informationThe feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients
The feasibility of circulating tumour DNA as an alternative to biopsy for mutational characterization in Stage III melanoma patients ASSC Scientific Meeting 13 th October 2016 Prof Andrew Barbour UQ SOM
More informationHistology independent indications in oncology. The BRAF Story. Yibing Yan PhD Roche / Genentech
Histology independent indications in oncology The BRAF Story Yibing Yan PhD Roche / Genentech 1 Introduction the discovery Case study in BRAF mutant melanoma heterogeneity within the tumour variability
More informationResponse and resistance in melanoma. Helen Rizos
Response and resistance in melanoma Helen Rizos RESISTANCE: Kinase inhibitors PI3K only 5% MAPK+PI3K 20% Unknown 38% MAPK 37% BRAF amplification 15% 111 pati ents 100 BRA F inhibitor 11 BRAF+MEK inhibitor
More informationLiquid Biopsy. Jesus Garcia-Foncillas MD PhD. Director
Liquid Biopsy Jesus Garcia-Foncillas MD PhD Director Main issues about liquid biopsies New paradigm: Precision Medicine Heterogeneity & Dynamics Surrogate mirror for the tumor CTCs in colon cancer ctdna:
More informationIntroduction to liquid biopsy in a Specialized Cancer Center
Introduction to liquid biopsy in a Specialized Cancer Center Dr. Antonio Cubillo Head, Medical OncologyDepartment HM-CIOCC In collaboration with OUTLINE Need Liquid Biopsy: Definition and techniques Sensitivity
More informationCirculating Tumor DNA in GIST and its Implications on Treatment
Circulating Tumor DNA in GIST and its Implications on Treatment October 2 nd 2017 Dr. Ciara Kelly Assistant Attending Physician Sarcoma Medical Oncology Service Objectives Background Liquid biopsy & ctdna
More informationSupplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
More informationRobert Beer
Robert Beer Robert.beer@wales.nhs.uk All Wales Medical Genetics Service Genetic Technologist Training Day 22 nd November 2017 Contents Stratified Medicine NHS EGFR Diagnostic Testing Services Cell free
More informationEnterprise Interest No
Enterprise Interest No SY-05 Pulmonary Pathology: Options for targeted therapy in lung cancer Liquid biopsy in thoracic oncology Where are we now? Paul Hofman Laboratory of Clinical and Experimental Pathology
More informationLa biopsia liquida dei tumori: il viaggio. Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome
La biopsia liquida dei tumori: il viaggio Paola Gazzaniga Liquid Biopsy Unit Dept. Molecular Medicine Sapienza University of Rome Must Know Necessary Travel Tips There is lack of drugs to treat all the
More informationctbraf Mutation Assay
The first and only fully automated liquid biopsy assay ctbraf Idylla ctbraf Mutation Assay The easiest solution to implement liquid biopsy testing The potential of liquid biopsy The use of liquid biopsies
More informationBest Practices in the Treatment and Management of Metastatic Melanoma. Melanoma
Best Practices in the Treatment and Management of Metastatic Melanoma Philip Friedlander MD PhD Director of Melanoma Medical Oncology Program Assistant Professor Division of Hematology Oncology Assistant
More informationCDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018
CDx in oncology Prof. Christophe Le Tourneau, MD, PhD Institut Curie Paris & Saint-Cloud France Head, Department of Drug Development and Innovation (D 3 i) INSERM U900 Research unit Versailles Saint-Quentin-en-Yvelines
More informationTransforming Oncology With Precision Medicine Solutions. Company Overview January 2017
Transforming Oncology With Precision Medicine Solutions Company Overview January 2017 FORWARD-LOOKING STATEMENTS Statements in this presentation about the Company's expectations, applications of its technology,
More informationANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria
IS IT TIME TO RE-CHALLENGE ANTI-EGFR IN MCRC? Assoc. Prof. Gerald Prager, Medical University of Vienna, Austria Dr. Andrea Sartore-Bianchi, Oncologia Clinica Molecolare, Niguarda Cancer Center, Milano,
More informationMolecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
More informationBRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy
Medical Policy Manual Genetic Testing, Policy No. 41 BRAF Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy Next Review: August 2019 Last Review: July 2018 Effective: August 1,
More informationSupplementary Online Content
Supplementary Online Content Venook AP, Niedzwiecki D, Lenz H-J, et al. Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced
More informationMelanoma: From Chemotherapy to Targeted Therapy and Immunotherapy. What every patient needs to know. James Larkin
Melanoma: From Chemotherapy to Targeted Therapy and Immunotherapy What every patient needs to know James Larkin Melanoma Therapy 1846-2017 Surgery 1846 Cytotoxic Chemotherapy 1946 Checkpoint Inhibitors
More informationQué hemos aprendido hasta hoy? What have we learned so far?
Qué hemos aprendido hasta hoy? What have we learned so far? Luís Costa Hospital de Santa Maria & Instituto de Medicina Molecular Faculdade de Medicina de Lisboa Disclosures Research Grants: Amgen; Novartis;
More informationDNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA
DNA Methylation of Tumor Suppressor and Metastasis Suppressor Genes in Circulating Tumor Cells and corresponding Circulating Tumor DNA Maria Chimonidou 1, Areti Strati 1, Nikos Malamos 2, Vasilis Georgoulias
More informationThe OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific
The OncoBEAM RAS liquid biopsy experience in real-world clinical practice Frederick S. Jones, Ph.D., Global Director, Medical Scientific Affairs,Sysmex 2 OncoBEAM liquid biopsy: circulating tumor DNA (ctdna)
More informationPlasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc)
Plasma ctdna RAS/RAF mutations analysis for monitoring overall survival (OS) and heterogeneity in metastatic colorectal cancer patients (mcrc) Authors: Andrea Petricca Mancuso, Veronica Varchetta, Fabrizio
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationNext generation diagnostics Bringing high-throughput sequencing into clinical application
Next generation diagnostics Bringing high-throughput sequencing into clinical application Leonardo A. Meza-Zepeda, PhD Translational Genomics Group Institute for Cancer Research Leonardo.Meza-Zepeda@rr-research.no
More informationTargeted Therapies in Melanoma
Mutations and Targets Targeted Therapies in Melanoma ckit NRAS
More informationUpdate on Targeted Therapy in Melanoma
Update on Targeted Therapy in Melanoma Seville June 2013 James Larkin FRCP PhD London UK Overview What are the targets in melanoma? BRAF / KIT / NRAS / GNAQ / MEK DNA / microtubules CTLA4 / PD1 / PDL1
More informationClinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease
ECD International Medical Symposium New York City October 26, 2017 Clinical molecular profiling of archival tumor tissue and cell-free DNA from patients with Erdheim-Chester disease Filip Janku, Eli Diamond,
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationBiopsia Líquida: Oncología en Tiempo Real. Federico Rojo Fundación Jiménez Díaz
Biopsia Líquida: Oncología en Tiempo Real Federico Rojo Fundación Jiménez Díaz Liquid Biopsy in Cancer Liquid Biopsy in Cancer Publication Date: April 5, 2016 Blood Tests replace Surgical Biopsies to create
More informationSee how you can guide the path her cancer takes
See how you can guide the path her cancer takes 1 Idylla : easy, rapid and accurate molecular medicine for every patient Paola Valente Strategic Marketing Biocartis 6th meeting on external quality assessment
More informationDevelopment of Circulating Tumor DNA
Development of Circulating Tumor DNA Title of presentation Arial Bold 30pt in White Biomarkers Secondary title 22pt using Arial Next in White Generation Sequencing Brian Dougherty PhD, MBA Translational
More informationDiagnostic with alternative sample types (liquid biopsy)
MOLECULAR DIAGNOSTICS OF EGFR AND T790M MUTATIONS CHALLENGES AND SOLUTIONS Diagnostic with alternative sample types (liquid biopsy) James CH Yang, MD, PhD Director, Professor, Graduate Institute of Oncology
More informationLukas Bubendorf Pathologie. Liquid biopsies
Lukas Bubendorf Pathologie Liquid biopsies Liquid biopsies 1. Circulating cell-free tumor-dna (ctdna) 2. Circulating tumor cells (CTC) Source: Sysmex CTCs ctdna ctrna exosomes Quantification Protein RNA
More informationIndividualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
More informationMET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
More informationMolecular Testing Updates. Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine
Molecular Testing Updates Karen Rasmussen, PhD, FACMG Clinical Molecular Genetics Spectrum Medical Group, Pathology Division Portland, Maine Keeping Up with Predictive Molecular Testing in Oncology: Technical
More informationHow can we reduce the mortality from melanoma in Australia?
How can we reduce the mortality from melanoma in Australia? Professor Grant McArthur MB BS PhD Peter MacCallum Cancer Centre Melbourne, Australia University of Melbourne, Parkville, Australia What is melanoma?
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationNormal RAS-RAF (MAPK) pathway signaling
BRAF-Mutations in Melanomas L. Mazzucchelli Istituto Cantonale di Patologia, Locarno 77. Annual Meeting Swiss Society of Pathology, Lucerne 2011 Sponsored by Roche Pharma Switzerland Melanoma has increased
More informationMetastasectomy for Melanoma What s the Evidence and When Do We Stop?
Metastasectomy for Melanoma What s the Evidence and When Do We Stop? Vernon K. Sondak, M D Chair, Moffitt Cancer Center Tampa, Florida Focus on Melanoma London, UK October 15, 2013 Disclosures Dr. Sondak
More informationManagement of Brain Metastases Sanjiv S. Agarwala, MD
Management of Brain Metastases Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA, USA Incidence (US):
More informationWork-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients
2018 AAD Annual Meeting, San Diego, CA Work-up/Follow-up: Baseline and Surveillance Studies for Cutaneous Melanoma Patients Susan M. Swetter, MD, FAAD Professor of Dermatology Director, Pigmented Lesion
More informationDr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory
Dr Yvonne Wallis Consultant Clinical Scientist West Midlands Regional Genetics Laboratory Personalised Therapy/Precision Medicine Selection of a therapeutic drug based on the presence or absence of a specific
More informationTransform genomic data into real-life results
CLINICAL SUMMARY Transform genomic data into real-life results Biomarker testing and targeted therapies can drive improved outcomes in clinical practice New FDA-Approved Broad Companion Diagnostic for
More informationDevelopment of Rational Drug Combinations for Oncology Indications - An Industry Perspective
Development of Rational Drug Combinations for Oncology Indications An Industry Perspective Stuart Lutzker, MDPhD Vice President Oncology Early Development Genentech Inc 1 Conventional Oncology Drug Development
More informationHow close are we to standardised extended RAS gene mutation testing? The UK NEQAS experience
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS experience Dr Susan D. Richman, Dr Jennifer Fairley, Dr Rachel Butler, Dr Zandra C. Deans Overview Introduction to UK NEQAS
More informationMedical Treatment for Melanoma Sanjiv S. Agarwala, MD
Medical Treatment for Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Disclosures None Overview
More informationFrequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
More informationAdvances in Pathology and molecular biology of lung cancer. Lukas Bubendorf Pathologie
Advances in Pathology and molecular biology of lung cancer Lukas Bubendorf Pathologie Agenda The revolution of predictive markers Liquid biopsies PD-L1 Molecular subtypes (non-squamous NSCLC) Tsao AS et
More informationIdentification of BRAF mutations in melanoma lesions with the Roche z480 instrument
Identification of BRAF mutations in melanoma lesions with the Roche z480 instrument Márta Széll IAP, Siófok May 14, 2012 Multifactorial skin diseses: much more frequent then genodermatoses exhibit familial
More informationResultados del estudio Concordance: Relevancia clínica de la determinación del ADNtc mediante la tecnología BEAMing. Ana Vivancos
Resultados del estudio Concordance: Relevancia clínica de la determinación del ADNtc mediante la tecnología BEAMing Ana Vivancos Circulating tumor DNA extended RAS mutational analysis as a surrogate of
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationKeynote Presentation I New Era of CRC Management: Impact of Tumor Sidedness and Molecular Subtypes of CRC
Keynote Presentation I New Era of CRC Management: Impact of Tumor Sidedness and Molecular Subtypes of CRC Scott Kopetz, MD, PhD, FACP University of Texas MD Anderson Cancer Center Houston, Texas, United
More informationThe Pathology of Neoplasia Part II
The Pathology of Neoplasia Part II February 2018 PAUL BOGNER, MD A S S O C I A T E P R O F E S S O R O F O N C O L O G Y P A T H O L O G Y A N D D E R M A T O L O G Y Clinical goals of cancer pathology
More informationCTC in clinical studies: Latest reports on GI cancers
CTC in clinical studies: Latest reports on GI cancers François-Clément Bidard, MD PhD GI cancers are characterized by Multimodal treatment strategies Treatments are adapted to tumor burden & prognosis
More informationKEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl
PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016
More informationThe Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma
The Development of Encorafenib (LGX818) and Binimetinib (MEK162) in Patients With Metastatic Melanoma Reinhard Dummer, 1 Keith Flaherty, 2 Richard Kefford, 3 Paolo A. Ascierto, 4 Laure Moutouh-de Parseval,
More informationPrecision Genetic Testing in Cancer Treatment and Prognosis
Precision Genetic Testing in Cancer Treatment and Prognosis Deborah Cragun, PhD, MS, CGC Genetic Counseling Graduate Program Director University of South Florida Case #1 Diana is a 47 year old cancer patient
More informationVertical Magnetic Separation of Circulating Tumor Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients
Vertical Magnetic Separation of Circulating Cells and Somatic Genomic-Alteration Analysis in Lung Cancer Patients Chang Eun Yoo 1,2#, Jong-Myeon Park 3#, Hui-Sung Moon 1,2, Je-Gun Joung 2, Dae-Soon Son
More informationMelanoma: Therapeutic Progress and the Improvements Continue
Melanoma: Therapeutic Progress and the Improvements Continue David W. Ollila, MD Professor of Surgery Jesse and James Millis Professor of Melanoma Research May 20, 2016 Disclosures: NONE Outline 2016 Therapeutic
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationImmunotherapy of Melanoma Sanjiv S. Agarwala, MD
Immunotherapy of Melanoma Sanjiv S. Agarwala, MD Professor of Medicine Temple University School of Medicine Chief, Oncology & Hematology St. Luke s Cancer Center, Bethlehem, PA Overview Metastatic Melanoma
More informationResults you can trust
PRODUCT I NF OR MAT ION pharmdx Results you can trust The first and only FDA-approved PD-L1 test to assess the magnitude of treatment effect on progression-free survival in melanoma patients from OPDIVO
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal (STA) Dabrafenib for treating unresectable, advanced or metastatic BRAF V600 mutation-positive melanoma mutation-positive melanoma
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationWat is de potentiële waarde van ctdna? PLCRC - MEDOCC
Wat is de potentiële waarde van ctdna? PLCRC - MEDOCC Translational Gastrointestinal Oncology Remond Fijneman r.fijneman@nki.nl Department of Pathology, Amsterdam, NL Wat is de potentiële waarde van ctdna?
More informationPros and cons of liquid biopsy: Ready to replace tissue?
Pros and cons of liquid biopsy: Ready to replace tissue? 2-Day Molecular Biologists Symposium: Liquid biopsies Federico Rojo Enterprise Interest No disclosures. Biological limitations for molecular testing:
More informationMonitoring of KRAS-mutated ctdna to discriminate pseudoprogression from true progression during anti-pd-1 treatment of lung adenocarcinoma
/, 2017, Vol. 8, (No. 23), pp: 38056-38060 Monitoring of KRAS-mutated ctdna to discriminate pseudoprogression from true progression during anti-pd-1 treatment of lung adenocarcinoma Nicolas Guibert 1,2,4,
More informationOverall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma
Overall Survival in COLUMBUS: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) vs Vemurafenib () or ENCO in BRAF-Mutant Melanoma, Paolo A. Ascierto, Helen J. Gogas, Ana Arance, Mario Mandala,
More informationA better clinical pathway for cancer monitoring. Antonius Schuh, Ph.D. Chief Executive Officer December 2013
A better clinical pathway for cancer monitoring Antonius Schuh, Ph.D. Chief Executive Officer December 2013 DISCLAIMER Forward-Looking Statements Statements in this presentation about the Company's expectations,
More informationThe Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw
The Cancer Research UK Stratified Medicine Programme: Phases One and Two Dr Emily Shaw Introduction The CRUK Stratified Medicine Programme: SMP1 rationale, design and implementation The role of the cellular
More informationCirculating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Circulating Tumor DNA for Management of Non-Small-Cell Lung Cancer (Liquid Biopsy) Policy Number: 2.04.143 Last Review: 1/2019 Origination: 1/2018 Next Review: 1/2020 Policy Blue Cross and Blue Shield
More informationECMC cfdna consensus meeting
ECMC cfdna consensus meeting State of the art for cfdna technologies 24 th November 2014 Applications of ctdna analysis for drug development Potential of ctdna analysis to: Identify the right patients
More informationMP Circulating Tumor DNA Management of Non-Small-Cell Lung Cancer (Liquid Biopsy)
Medical Policy BCBSA Ref. Policy: 2.04.143 Last Review: 10/18/2018 Effective Date: 10/18/2018 Section: Medicine Related Policies 2.04.121 Miscellaneous Genetic and Molecular Diagnostic Tests 2.04.45 Molecular
More informationMELANOMA: THE BEST OF THE YEAR Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone
MELANOMA: THE BEST OF THE YEAR 2018 Dott.ssa Silvia Quadrini UOC Oncologia ASL Frosinone The Best of the Year 2018: MELANOMA CHIRURGIA TERAPIA ADIUVANTE TERAPIA PER MALATTIA AVANZATA The Best of the Year
More information3/23/2017. Disclosure of Relevant Financial Relationships. Pathologic Staging Updates in Lung Cancer T STAGE OUTLINE SURVIVAL ACCORDING TO SIZE ONLY
Pathologic Staging Updates in Lung Cancer Disclosure of Relevant Financial Relationships USCAP requires that all planners (Education Committee) in a position to influence or control the content of CME
More informationBRAF Gene Mutation Testing To Select Melanoma or Glioma Patients for Targeted Therapy
BRAF Gene Mutation Testing To Select Melanoma or Glioma Patients for Targeted Therapy Policy Number: 2.04.77 Last Review: 12/2017 Origination: 4/2013 Next Review: 12/2018 Policy Blue Cross and Blue Shield
More informationNew paradigms for treating metastatic melanoma
New paradigms for treating metastatic melanoma Paul B. Chapman, MD Melanoma Clinical Director Melanoma and Immunotherapeutics Service Memorial Sloan Kettering Cancer Center, New York 20 th Century Overall
More information